NCT06934889View on ClinicalTrials.gov

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
GlioblastomaGliosarcoma
Interventions
DRUG

ERAS-801

will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.

DRUG

ABBV-637

will be administered intravenously over one hour (+/- 10 min) once every 28 days on the first day of the new cycle.

DRUG

ABBV-155

will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.

DRUG

Temozolomide

Temozolomide will be continued for 6 cycles after radiation.

RADIATION

Radiotherapy

will be given as per standard of care radiation for GBM

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER